HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 459 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Breast Cancer Patient Who Continued Teaching Throughout Her Treatment Wins Teacher... February 9, 2021 Wistful Facebook Comment Sends Volunteers Flocking To Help MS Patient Fulfill... November 12, 2019 ΙΣΤΟΡΙΑ January 18, 2019 Why haven’t we cured cancer? June 20, 2022 Load more HOT NEWS New Study Finds Dogs Can Sniff Out Lung Cancer — And... Studies Show Immunotherapy Improves Long-Term Survival in Growing Number of Cancers Researchers Create Modified Antibodies to Target RAS and p53 in Cancer Identification of Actionable Molecular Alterations in NCI-MATCH
